TODD STRATEGY GROUP

Lobbying for GENENTECH, INC. · Biotechnology corporation.

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · District of Columbia · House · Senate · $60,000.00 income · posted Jan 20, 2026

Lobbying activity 2

Pharmacy

Prescription drug payment reform. Supply chain. Strategic National Stockpile.

Medicare/Medicaid

Medicare and Medicaid payment issues. 340B. Implementation of Inflation Reduction Act of 2022.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.